Go Pro

Cybin (NASDAQ:HELP) Stock Rating Upgraded by Wall Street Zen

Cybin logo with Healthcare background
Image from MarketBeat Media, LLC.

Key Points

  • Wall Street Zen upgraded Cybin from “strong sell” to “sell,” while the broader analyst consensus remains “Buy” with an average price target of $48.60.
  • Cybin shares fell 8.0% to $12.18, despite trading well above their 12-month low of $3.76; the stock’s 12-month high is $14.35.
  • The company reported a quarterly loss of $0.91 per share, missing the $0.80 consensus estimate, and analysts expect a full-year loss of $2.95 per share. Institutional investors own 17.94% of Cybin.
  • Five stocks to consider instead of Cybin.

Cybin (NASDAQ:HELP - Get Free Report) was upgraded by research analysts at Wall Street Zen from a "strong sell" rating to a "sell" rating in a report released on Saturday.

Other analysts have also issued research reports about the company. Wells Fargo & Company assumed coverage on Cybin in a research report on Monday, July 27th. They set an "overweight" rating and a $16.00 price objective on the stock. TD Cowen lifted their target price on Cybin from $8.00 to $62.00 and gave the company a "buy" rating in a report on Thursday, August 20th. Five analysts have rated the stock with a Buy rating, According to MarketBeat.com, Cybin currently has an average rating of "Buy" and a consensus target price of $48.60.

Get Our Latest Report on Cybin

Cybin Trading Down 8.0%

Cybin stock traded down $1.06 during midday trading on Friday, reaching $12.18. 1,452,450 shares of the stock traded hands, compared to its average volume of 1,941,074. The firm has a market cap of $889.87 million, a PE ratio of -4.03 and a beta of 0.55. The company has a 50-day simple moving average of $8.69 and a two-hundred day simple moving average of $6.48. Cybin has a 12-month low of $3.76 and a 12-month high of $14.35.

Cybin (NASDAQ:HELP - Get Free Report) last issued its quarterly earnings results on Friday, August 14th. The company reported ($0.91) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.80) by ($0.11). Equities research analysts anticipate that Cybin will post -2.95 earnings per share for the current year.

Institutional Investors Weigh In On Cybin

Hedge funds and other institutional investors have recently modified their holdings of the company. Osaic Holdings Inc. grew its stake in shares of Cybin by 46.7% during the second quarter. Osaic Holdings Inc. now owns 7,543 shares of the company's stock worth $63,000 after purchasing an additional 2,400 shares in the last quarter. AXQ Capital LP acquired a new stake in Cybin in the second quarter valued at $75,000. Bank of America Corp DE raised its stake in Cybin by 66.8% in the second quarter. Bank of America Corp DE now owns 29,443 shares of the company's stock valued at $247,000 after buying an additional 11,790 shares in the last quarter. Pale Fire Capital SE purchased a new stake in Cybin during the 2nd quarter worth about $1,015,000. Finally, Millennium Management LLC lifted its holdings in Cybin by 1,388.5% during the 4th quarter. Millennium Management LLC now owns 1,028,549 shares of the company's stock worth $8,414,000 after buying an additional 959,448 shares during the last quarter. 17.94% of the stock is currently owned by institutional investors and hedge funds.

Cybin Company Profile

(Get Free Report)

Cybin Inc is a clinical-stage biopharmaceutical company focused on the development of psychedelic-based therapeutics for the treatment of mental health disorders. Headquartered in Toronto and listed on the NASDAQ under the symbol HELP, Cybin pursues research and development programs intended to harness the therapeutic potential of psychedelic compounds to address conditions with significant unmet need.

The company operates a drug discovery and development platform aimed at creating novel small-molecule psychedelic analogs and tailored formulations.

Further Reading

Analyst Recommendations for Cybin (NASDAQ:HELP)

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Continue following MarketBeat
Add MarketBeat as your preferred source on Google to see our latest stories in your feed.

Should You Invest $1,000 in Cybin Right Now?

Before you consider Cybin, you'll want to hear this.

MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Cybin wasn't on the list.

While Cybin currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys.

View The Five Stocks Here

(Almost)  Everything You Need To Know About The EV Market Cover

Looking to profit from the electric vehicle mega-trend? Click the link to see our list of which EV stocks show the most long-term potential.

Get This Free Report
Like this article? Share it with a colleague.

Featured Articles and Offers

Recent Videos

Stock Lists

All Stock Lists

Investing Tools

Calendars and Tools

Search Headlines